Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant748 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,432 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02725489 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | completed | Phase 2 | 13 | Mary Crowley Medical Research CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 |
| NCT03593681 | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy(nCYT) | completed | — | 150 | Boston Scientific CorporationINDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04716374 | Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer(PaVaClO) | completed | — | 550 | Hellenic Cooperative Oncology GroupOTHER | 0 | Jan 20, 2021 | clinicaltrials |
| NCT04351139 | Impact of the COVID-19 Pandemic in Gynecological Oncology(COVID-GYN) | completed | — | 205 | Hospices Civils de LyonOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03742713 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer(CINOVA) | completed | Phase 2 | 25 | Cristal TherapeuticsINDUSTRY | 3 | Dec 28, 2020 | clinicaltrials |
| NCT00420381 | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | completed | Phase 3 | 829 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 17, 2020 | clinicaltrials |
| NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 28 | Rachel MillerOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT01068483 | Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | completed | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT04032600 | Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics(ATLANTIS) | completed | N/A | 61 | Charite University, Berlin, GermanyOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT00227721 | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 30 | Robert MorrisOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02399592 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer(Toco-Ovar) | completed | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT00436215 | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00058032 | CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women(UKCTOCS) | completed | N/A | 202,638 | University College, LondonOTHER | 0 | Nov 19, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT00879840 | Assessment of Screening Modalities for Gynecologic Cancers | completed | — | 118 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2020 | clinicaltrials |
| NCT00340600 | Continuation of Follow-up of DES-Exposed Cohorts | completed | — | 10,805 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2020 | clinicaltrials |
| NCT00508378 | Chemotherapy-Related Toxicities In Ovarian Cancer Patients | completed | — | 288 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03704467 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | completed | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Nov 13, 2020 | clinicaltrials |
| NCT04626895 | Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers | completed | N/A | 15 | Medstar Health Research InstituteOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT02560818 | Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer(CASOHAR) | completed | N/A | 20 | Centre Francois BaclesseOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT00444054 | The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer(RECHARGE) | completed | N/A | 10 | Albert Einstein College of MedicineOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT01768156 | Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer(Meta-Four) | completed | N/A | 101 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT00391118 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | completed | Phase 2 | 153 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT01461850 | Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm(SCORPION) | completed | Phase 3 | 171 | Catholic University of the Sacred HeartOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT04237090 | Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel(PREMED-F1) | completed | Phase 3 | 27 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02560337 | Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.(CaTo-ROC) | completed | Phase 2 | 26 | Vejle HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04573933 | Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.(BREIZH-PARPi) | completed | — | 54 | University Hospital, BrestOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02163720 | Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) | completed | — | 101 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT01441154 | Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment | completed | — | 16 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2020 | clinicaltrials |
| NCT01787656 | A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus | completed | — | 438 | University of South AlabamaOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01616303 | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | completed | Phase 2 | 97 | Quest PharmaTech Inc.INDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | completed | Phase 1 | 36 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00340210 | Extended Follow-up of Columbia, MO Serum Bank Participants | completed | — | 6,720 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2020 | clinicaltrials |
| NCT00801320 | Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | N/A | 100 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01139957 | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer | completed | — | 1,916 | Gynecologic Oncology GroupNETWORK | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02297958 | Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma(IFFaLCCO) | completed | — | 28 | Rennes University HospitalOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT02121990 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 1 | 37 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT04507191 | PDL1 in Ovarian High Grade Serous Carcinoma | completed | — | 54 | Port Said University hospitalOTHER | 1 | Aug 11, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2021source: clinicaltrials